
ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…